Melanotan II: A Complete Guide to Peptide-Enhanced Tanning

Melanotan II (MT-II) is a laboratory-developed version of alpha-melanocyte-stimulating hormone (a-MSH), initially created at the University of Arizona in the early 1990s. Investigation of Melanotan II benefits began with a straightforward question: whether a peptide that promotes melanin synthesis (the pigment that determines skin color) helps protect people with fair skin from UV-induced cellular damage by enabling them to achieve a photoprotective pigmentation with less sun exposure?

The resulting compound was found to promote melanogenesis (the production of melanin), but researchers also observed several unexpected biological responses. Since then, Melanotan II has been investigated for a range of biological activities outside skin darkening.

How Melanin Production Works

To understand how does Melanotan II work, it helps to first understand the body’s normal tanning response. When UV radiation reaches your skin, it damages the DNA of keratinocytes (the main cells in the outer layer of the skin). These cells release a-MSH, which binds to melanocortin 1 receptors (MC1R) on nearby melanocytes (the cells that produce pigment). This activates a signaling pathway involving cAMP and MITF, increasing the synthesis of eumelanin, the dark brown pigment that absorbs UV radiation and helps protect surrounding cells from further DNA injury.

Understanding this process also explains why tanning peptides have become an area of investigation. A natural tan is a response to UV-induced skin damage: the more UV exposure, the greater the stimulation of pigment synthesis. The challenge is that meaningful melanogenesis typically requires substantial UV exposure, and that same exposure is associated with an increased risk of DNA damage, photoaging, and skin cancer.

Melanotan II’s Mechanism of Action

Melanotan II is a non-selective melanocortin receptor agonist, meaning it activates multiple melanocortin receptors (MC1R through MC5R). Its tanning effect is primarily linked to activation of MC1R on melanocytes, stimulating eumelanin formation rather than relying on UV-induced DNA damage as the initial trigger.

Instead of relying on UV exposure to initiate the signaling cascade, it activates the same biological pathway directly. This may reduce the amount of UV exposure needed to stimulate melanin synthesis.

MC1R Activation (Tanning)

The primary effect is signaling through MC1R (melanocortin 1 receptor), which increases eumelanin production in melanocytes, leading to progressive skin darkening. A Melanotan II guide should also distinguish the pigment produced from a cosmetic color change: it is the same naturally occurring eumelanin generated during the body’s tanning response.

Because eumelanin absorbs UV radiation, increased pigmentation may provide some additional photoprotection. However, current evidence does not support assigning a specific SPF value to Melanotan II-induced tanning.

MC3R and MC4R Activation (Secondary Effects)

Since Melanotan II is a non-selective melanocortin receptor agonist, it also activates MC3R and MC4R in the central nervous system. Binding to MC1R has been associated with two well-documented secondary effects:

• Appetite suppression. MC4R is the same receptor targeted by setmelanotide, an FDA-approved treatment for certain rare genetic forms of obesity. Melanotan II has been shown to reduce appetite through hypothalamic pathways (brain regions involved in regulating hunger), although this was not its original intended purpose.
• Increased libido. MC4R also plays a role in sexual arousal pathways. This effect led to the development of PT-141 (bremelanotide), a modified analogue of Melanotan II that was later approved by the FDA for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

What the Research Shows

Tanning Efficacy

Clinical studies found that Melanotan II increased skin darkening in human participants by stimulating melanin production. In the Phase I trial, visible pigmentation was observed after five subcutaneous doses administered every other day. The degree of tanning varied between volunteers and appeared more noticeable in fair-skinned participants.

UV Protection

Increased eumelanin synthesis is expected to provide the same biological functions as naturally produced eumelanin, including absorption of UV radiation. However, clinical evidence demonstrating increased UV resistance or reduced skin cancer risk specifically following Melanotan II treatment remains limited.

Fitzpatrick Type I Considerations

Those with Fitzpatrick type I skin (very fair skin that burns easily and rarely or never tans naturally) often carry MC1R gene variants linked to reduced tanning responses to UV exposure.

Studies have shown that melanocortin analogues can still significantly increase melanin density in people with these variants (p < 0.001), although the degree of pigmentation varies between individuals. Melanotan II results may therefore differ according to underlying genetics rather than Fitzpatrick skin type alone.

Side Effects and Safety Considerations

As with any biologically active peptide, Melanotan II has documented side effects that should be considered alongside its reported effects on pigment deposition. Most have been described in clinical trials and observational reports.

Common Initial Effects

• Nausea. The most frequently reported side effect, particularly during the first few administrations. It is dose-dependent and typically resolves within about an hour.
• Facial flushing. Temporary reddening of the face, usually lasting less than an hour. The exact mechanism is not fully understood but is thought to involve melanocortin receptor activation and vascular effects.
• Appetite suppression. Associated with activation of MC4R (melanocortin 4 receptor), which helps regulate hunger. Depending on the context, this may be viewed as either a side effect or a secondary pharmacological effect.

Notable Concerns

• Darkening of moles. Increased pigmentation may also affect existing moles (melanocytic nevi). Although this is usually a cosmetic change, any new or changing mole should be evaluated by a dermatologist.
• Uneven pigmentation. Patchy or uneven tanning has been reported in some individuals, particularly during the early stages of pigmentation.
• Spontaneous erections. In the original Phase I study, 9 of 17 healthy male participants experienced spontaneous erections following Melanotan II dosage administration. This observation ultimately led to the development of PT-141.

The Skin Cancer Question

The relationship between this compound and skin cancer risk remains uncertain. Part of understanding what is Melanotan II is recognizing the difference between established findings and theoretical considerations.

• Potential benefit. It has been suggested that, by promoting the production of eumelanin with reduced UV exposure, Melanotan II may help reduce UV-induced DNA damage. However, no prospective human studies have demonstrated that it reduces the incidence of melanoma or other skin cancers.
• Potential concern. Darkening of existing moles, the appearance of multiple new moles, and at least five cases of melanoma have been reported during Melanotan II use. These reports do not establish a cause-and-effect relationship. Moreover, all published melanoma cases involved additional risk factors, such as fair skin, tanning bed use, or a family history of the disease.
• Eumelanin vs. pheomelanin. This compound primarily stimulates eumelanin (the pigment that absorbs more UV radiation) rather than pheomelanin (the pigment associated with lower photoprotection). Although eumelanin is well known for its photoprotective properties, this does not mean that the peptide protects against skin cancer.

There is insufficient information regarding the long-term safety of this peptide or its effect on skin cancer risk. Regular skin examinations are recommended, especially for people with numerous or atypical moles.

Key Takeaways

• Activation of MC1R increases the production of eumelanin, the pigment responsible for tanning.
• Human studies found visible tanning after five subcutaneous doses. Even then, Melanotan II benefits were not the same for everyone.
• Appetite suppression and increased libido are linked to MC4R rather than MC1R.
• Nausea is the side effect reported most often. Facial flushing, mole darkening, and uneven pigmentation have also been observed.
• There is still no evidence showing whether Melanotan II changes long-term skin cancer risk.
• MC1R gene variants can influence the amount of pigmentation that develops.

Clinical References

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME.
Life Sciences, 1996;58(20):1777-1784. PubMed →

Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers
Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, et al.
Archives of Dermatology, 2004. PubMed →

Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles
Fitzgerald LM, Fryer JL, Halliday GM, et al.
Peptides, 2006. PubMed →

Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization
Hadley ME, Dorr RT.
Peptides. 2006;27(4):921-930. PubMed →

An overview of benefits and risks of chronic melanocortin-1 receptor activation
Bohm M, et al.
Journal of the European Academy of Dermatology and Venereology. 2024;39(1):39-51. PMC →